past successes

We are excited to share our success

Pfizer B7471014

Pfizer B7471014               

Started: 11/2020

Study Name: A phase 3, single-arm trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy children 15 months through 17 years of age

Indication: Pneumococcal

Principal Investigators: Luke Anschutz, Dave Meduna

Paidion FB401-01

Started: 11/2020

Study Name: A randomized, double-blind, placebo-controlled, multicenter, 16-week trial to evaluate the efficacy and safety of xxx in children, adolescent and adult subjects (ages 2 years and older) with mild to moderate atopic dermatitis

Indication: Atopic Dermatitis

Principal Investigator: Sahra Niazi

Pfizer C3671008

Started: 3/2020

Study name: A phase 3, randomized, double- or observer-blinded, placebo-controlled trial to evaluate the efficacy and safety of a respiratory syncytial virus (rsv) perfusion subunit vaccine in infants born to women vaccinated during pregnancy

Indication: RSV/OB

Principal Investigator: Brad Brabec

Pfizer B7471011

Started: 2/2020

Study name: A phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in healthy infants

Indication: Pneumococcal

Principal Investigators: Brad Brabec, Dave Meduna

Sanofi Pasteur MET59

Started: 9/2019

Study Name: Immunogenicity and Safety of a Booster Dose of an Investigational xxx Meningococcal Conjugate Vaccine in Adolescents and Adults

Indication: Meningitis

Principal Investigators: Paul Bernhardson, Brad Brabec, Steve Russell

Astra Zeneca Melody D5290C00004

Started: 9/2019

Study Name: A phase 3 randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of xxx, a monoclonal antibody with an extended half-life against respiratory syncytial virus, in healthy late preterm and term infants (melody)

Indication: RSV

Principal Investigator: Steve Russell

Kimberly Clark 39320.00

Started: 9/2019

Study name: A longitudinal study to evaluate various skin health biophysical measures preceding diaper dermatitis in newborns

Indication: None Specified Skin Study

Principal Investigator:  Amy Bargen

Kimberly Clark 39322.00

Started: 9/2019

Study Name: An exploratory study to identify the composition of the microbiome of healthy diapered skin in eight to twelve month old infants.

Indication: None Specified Skin Study

Principal Investigator: Amy Bargen

Pfizer C3671003

Started: 9/2019

Study Name A phase 2b, randomized, placebo-controlled, observer-blinded trial to evaluate the safety, tolerability, and immunogenicity of a respiratory syncytial virus (rsv) vaccine in pregnant women 18 through 49years of age and their infants

Indication: RSV/OB

Principal Investigator: Brad Brabec

GSK ROTA-96

Started: 6/2019

Study Name: A phase III, observer-blind, randomized, multi-country study to assess the  reactogenicity and safety of the Porcine circovirus (PCV) free liquid formulation of GSK’s oral live attenuated human rotavirus (HRV) vaccine as compared to the xxx the GSK’s HRV vaccine, when administered as a 2-dose vaccination in infants starting at age 6-12 weeks.

Indication: RSV

Principal Investigators: Sahra Niazi, Steve Russell, Pam Zegers

LOCATIONS

3262 Salt Creek Circle, Lincoln, NE 68504
4020 Hohensee Drive, Lincoln, NE 68516
8201 Northwoods Drive, Lincoln, NE 68505
1336 West A St, Suite B Lincoln, NE 68522

Phone: 402-465-5600
Fax: 402-327-6074

CONNECT

Phone: 402-465-5600
Fax: 402-327-6074

OFFICE HOURS

Clinic Hours-Weekdays
8:45 am to 4:30 pm Monday – Friday

Clinic Hours-Weekends
Northwoods and West A Locations Only
9:00 am to 4:00 pm Saturday
10:00 am to 2:00 pm Sunday

Clinic Hours-Evenings
West A Location Only
Monday – Thursday starting at 5:30 pm

Phone Hours
8:00 am to 5:00 pm Monday – Friday
8:30 am to 3:30 pm Saturday
9:30 am to 1:30 pm Sunday

After hours - call 402-465-5600 and choose option 1 to reach Telephone Line to Care.